Healthy
Conditions
Brief summary
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of PF-06946860 in healthy adult subjects following single ascending doses This is the first clinical study of PF-06946860.
Interventions
BIOLOGICALPF-06946860
PF-06946860 administered subcutaneously
OTHERPlacebo
Placebo, administered subcutaneously
Sponsors
Pfizer
Study design
Allocation
RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
BASIC_SCIENCE
Masking
TRIPLE (Subject, Caregiver, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
Yes
Inclusion criteria
Key Inclusion Criteria: * Healthy female subjects of nonchildbearing potential and/or male subjects who, at the time of screening, are between the ages of 18 and 55 years, inclusive * Body mass index (BMI) within 17.5 to 30.5 kg/m2; and a total body weight \>50 kg (110 lb) * Evidence of a personally signed and dated informed consent document indicating that the subject has been informed of all pertinent aspects of the study * Subjects enrolling as Japanese must have four biologically Japanese grandparents born in Japan. Key
Exclusion criteria
* Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at the time of dosing. * History of allergic reactions to diagnostic or therapeutic protein or human albumin. * History of recurrent infections or active infection within 28 days of screening. * Exposure to live vaccines within 28 days of screening. * History of regular alcohol consumption or positive drug test * Treatment with an investigational drug within 30 days (or as determined by the local requirement) or 5 half lives preceding the first dose of IP (whichever is longer). * Fertile male subjects who are unwilling or unable to use a highly effective method of contraception for the duration of the study and for at least 28 days after the last dose. * Use of prescription or nonprescription drugs and dietary supplements within 7 days or 5 half lives (whichever is longer) prior to the first dose
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of participants experiencing AE. | Up 9 weeks post dose |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Maximum Observed Plasma Concentration (Cmax) | Baseline, up to 9 weeks post dose, as data permit | — |
| Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) | Baseline, up to 9 weeks post dose, as data permit | — |
| Time to Reach Maximum Observed Plasma Concentration (Tmax) | Baseline, up to 9 weeks post dose, as data permit | — |
| Plasma Decay Half-Life (t1/2) | Baseline, up to 9 weeks post dose, as data permit | Plasma decay half-life is the time measured for the plasma concentration to decrease by one half. |
| Incidence of development of ADA, and if necessary NAb, against PF-06946860 | Baseline, up to 9 weeks post-dose, as data permit | — |
Countries
United States
Outcome results
None listed